|Bid||10.35 x 1800|
|Ask||10.41 x 900|
|Day's range||10.21 - 10.46|
|52-week range||8.44 - 13.30|
|Beta (5Y monthly)||1.47|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||27 Nov 2017|
|1y target est||11.92|
At this time, I'd like to turn the conference over to Atabak Mokari. Today, we issued three press releases, one announcing the positive outcome of our 178 patients Phase 2 trial of relacorilant in combination with nab-paclitaxel to treat patients with platinum-resistant ovarian cancer. Second, announcing markedly decreased liver fat in patients in our Phase 2 trial of miricorilant as a potential treatment for nonalcoholic steatohepatitis or NASH, and the third, providing a clinical update and announcing our financial results for the first quarter.
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today published its 2020 Environmental, Social and Governance (ESG) Progress Report detailing the company’s efforts to advance health and equity, minimize its impact on the planet and dedicate itself to quality, ethics and transparency.
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the launch of its 250 mg and 500 mg strength generic Erythromycin tablets—a therapeutic equivalent for the reference listed drug (RLD) Erythromycin Tablets from Arbor Pharmaceuticals. Teva generic Erythromycin tablets are indicated to treat a variety of bacterial infections, and to prevent initial or recurrent attacks of rheumatic fever in patients allergic to penicillin.